Primate erythrocytes appear to play a role in the clearance of potentially pathogenic immune complexes (IC) from the circulation. This study was undertaken to compare the clearance from the circulation and tissue uptake of two monoclonal IC probes: one of which, IgGi-IC, was bound well by erythrocytes, the other of which, IgA-IC, was bound relatively poorly by erythrocytes. The IC probes were labeled with different iodine isotopes and infused either concommitantly or sequentially into the arterial circulation. The results indicate that, compared with IgGl-IC, IgA-IC bind less well to primate erythrocytes, are cleared from the circulation more quickly despite their smaller size, and show increased uptake in kidney and lung but decreased uptake in liver and spleen. Evidence is presented which suggests that this pattern of clearance from the circulation and systemic uptake of IgA-IC is the result of decreased binding of IgA-IC to circulating erythrocytes. These findings support the hypothesis that the primate erythrocyte-IC clearing mechanism may be critically important for the safe removal of IC from the circulation.
1. Abbreviations used in this paper: CR1, CR2, and CR3, complement receptors types 1, 2, and 3, respectively; DNBS, 2,4-dinitrobenzene sulfonic acid; DNP, dinitrophenol; ELISA, enzyme-linked immunoassay; IC immune complex; IgA-IC, IgA-containing IC; IgGI-IC, IgGl-containing IC. between IC and erythrocytes, or the failure of IC to interact with erythrocytes, remain to be determined. In an effort to better understand how erythrocyte-IC interactions are affected by the biophysical properties of IC, we prepared a panel of mouse monoclonal anti-dinitrophenol (DNP) antibodies and then formed IC with DNP-bovine serum albumin (DNP-BSA). Examination of the binding properties of the individual IC preparations in vitro revealed that IgA-containing IC (IgA-IC) were bound relatively poorly by primate erythrocytes compared with IgG 1-containing IC (IgG 1-IC). This observation presented the opportunity to compare the fate in vivo of an IC probe that bound well to erythrocytes compared with that of an IC probe that bound relatively poorly to erythrocytes. Thus, the present study was undertaken to determine if there was a relationship between the magnitude of IC to erythrocyte binding, the rate of IC clearance from the circulation, and tissue uptake of IC. The results indicated that, compared with IgGl-IC, IgA-IC were bound less well by primate erythrocytes in vivo and were cleared from the circulation more quickly, despite their smaller size. There was also an enhanced uptake ofIgA-IC in glomeruli. These data provide the first direct experimental evidence supporting the hypothesis that, in primates, the failure of IC to bind to erythrocytes results in the preferential uptake of these potentially pathogenic IC in vulnerable organs.
Methods
Preparation ofDNP-BSA DNP-BSA was prepared using 2,4-dinitrobenzene sulfonic acid (DNBS) as follows: equal amounts of '25I-BSA and potassium carbonate were added to phosphate-buffered saline (PBS) (pH 7.2) to achieve a final BSA concentration of 1 mg/ml. DNBS (Eastman Kodak Co., Rochester, NY) was then added. By varying the concentration of DNBS, as well as the incubation times at 370C, a panel of DNP-BSA compounds with varying hapten/carrier ratios was constructed. The reaction mixture was passed through a Dowex column to remove unreacted DNBS. The protein concentration was determined by the Lowry method and absorbance was measured at 360 nm for determination of DNP concentration. Specific activity was measured in a gamma scintillation spectrometer (model 5230, Packard Instrument Co, Inc., Downers Grove, IL). A preparation containing 25 DNP groups per BSA molecule was used to sensitize mice for hybridoma production, while preparations containing 40-60 DNP groups per BSA molecule were used to form IC.
IgGl. Balb/c mice were sensitized with DNP-BSA and hybridomas were produced by the procedure described by Kohler and Milstein (3) as modified by Chesebro et al. (4) . Anti-DNP antibody producing hybridomas were identified using a DNP-specific enzyme-linked immunoassay (ELISA). Wells containing hybridomas at limiting dilution were again screened for DNP reactivity, and cell populations in positive wells were expanded. These cells were used to produce IgG I-containing ascites fluid as described above for IgA.
The antigen specificity and isotype of monoclonal antibodies from donors selected by the ELISA assay were verified by gel diffusion. Ascites fluid from mice injected with DNP-specific clones formed precipitin lines with DNP-BSA, DNP-histone, and DNP-poly-L-lysine, but not with native BSA. The isotype was determined by first incubating anti-DNP monoclonal antibody and DNP25-BSA at equivalence, followed by solubilization of the washed precipitate in DNP25-BSA excess. The solubilized IC were then placed in a central well surrounded by antisera specific for murine y,, y2a, 72b, y3, a and A heavy chains (Zymed Laboratories, San Francisco, CA). The monoclonal antibody from the clone used in this study formed a sharp precipitin line with anti-ya serum only, while all isotype-specific antisera formed more diffuse precipitin lines with IC prepared with polyclonal mouse anti-DNP antiserum. The IgA antibody contained X light chains. The IgGI antibody contained K light chains.
Formation ofIC
BSA was labeled with 1251 or '3'I via the chloramine-T method as previously described (1) . The free unreacted 1251 or 1311 was removed using Dowex-l-Cl (Sigma Chemical Co., St. Louis, MO). Ascites fluid containing monoclonal antibody was combined with the '25I-DNP-BSA or '31I-DNP-BSA at equivalence. This reaction mixture was incubated at 37°C for 30 min, then at 4°C for 15 h. The resulting precipitate was centrifuged at 1,200 g for 10 min, washed once with PBS, and then centrifuged again at 1,200 g for 10 min. The precipitate was then resuspended in the original volume of PBS and centrifuged for 20 min at 10 g. The supernatant fluid was used as the IC preparation. To form a given IC preparation, typically 0.7 mg of 1251_ or '311-labeled DNP-BSA was reacted with an amount of ascites fluid needed to achieve conditions of equivalence. The amount of antigen in the IC solution infused in each of the in vivo clearance studies was -0.06 mg.
Binding ofIC to erythrocytes in vitro
The assay measuring the amount of IC binding to erythrocytes in vitro was performed as described previosuly (6) . Briefly, washed, packed erythrocytes (buffy coat cells removed), IC, and serum (complement source) were incubated at 37°C for 10 min. The mixture was then centrifuged on 65% iced percoll (density = 1.10 g/ml) to separate erythrocytebound from unbound IC, and the percent binding calculated (6) . In each in vitro experiment, portions of the IC-erythrocyte reaction mixtures were also incubated with heat-inactivated (56°C for 30 min) baboon serum to assess complement-independent binding. Negligible (<4%) binding occurred under these conditions. The 125I-DNP-BSA preparations ( (1, 2) .
Experimental protocol. The IgA-IC and IgG -IC solutions were adjusted before infusion so that each IC preparation contained 4 X 106 cpm in 15 ml. The dose of IC used in these experiments is regarded as a trace dose, since it is far below that which saturates erythrocyte CR1 or the hepatic phagocytic system (1, 2, 6 ). In addition, when larger doses of IC were given to the same primate in three sequential doses, there was no change in IC to erythrocyte binding, IC clearance from the circulation, or hepatic uptake ofIC (2) . Before infusing the IC, the primates were first infused with autologous 5"Cr-labeled erythrocytes, as described previously (1, 2) . The erythrocytes were allowed to circulate for a minimum of 20 min. The infusion of IC then commenced. In exps. 1-3, the IgA-IC ('31I-labeled) were infused into one port and the IgGl-IC (125I1 labeled) were infused into the other port ofthe aortic arch double-lumen catheter. The IC were delivered by a 2-syringe constant infusion pump that simultaneously delivered 15 (1) . All processing of blood samples was done within 2 h of completing the experiment. Arterial blood pressure was monitored throughout the experiments and was normal and stable in all protocols. At the end of exps. 4 and 5, the position of the hepatic and renal vein catheters was confirmed angiographically.
Processing ofblood samples. The procedure for assessing IC binding to erythrocytes was described previously (1, 2, 6) . Briefly, 0.5 ml ofwhole blood was placed on 2 ml of cold 65% percoll (density = 1.10 g/ml, Sigma Chemical Co.) and centrifuged at 350 g for 15 min. Under these conditions, an erythrocyte fraction (erythrocytes and IC bound to erythrocytes) migrates through the percoll to the bottom of the tube, while the leukocytes and IC not bound to erythrocytes remain on the surface ofthe percoll. The 5"Cr marker on the erythrocytes served as an indicator of the efficiency of the separation procedure. In all experiments, >99% ofthe 5'Cr was detected in the erythrocyte fraction, and <1% was present in the percoll fraction. The '25I-cpm and the '31I-cpm of the erythrocyte fraction and of the supernatant fluid were then determined in a gamma scintillation counter, and the percent of IC bound to erythrocytes was calculated as described previously (1, 2, 6) . Most Glomeruli were isolated by sieving techniques, as described previously (5) . Each glomerular preparation was inspected under the microscope and was found to be composed of at least 85% glomeruli.
Analytical techniques
Antibody affinity determination. Association constants were determined for the two antibodies by equilibrium dialysis (7) . Briefly, Plexiglass chambers were assambled from two complemetary halves, each containing an open end compartment with an 8,000-mol wt dialysis membrane (Spectrum Medical Industries, Los Angeles, CA) separating the two compartments. I ml of a given concentration of ascites fluid was added to one compartment of a series of chambers. To the opposite compartment was added I ml of 3H-DNP-lysine (New England Nuclear, Boston, MA), with each chamber containing a different concentration. The chambers were incubated at room temperature on a table top shaker.
At 24 h, duplicate 50-Mi samples were removed from each compartment and assayed for radioactivity. The concentration ofbound and free hapten was determined, and the inverse of these concentrations were plotted to determine association constants (8) .
Isoelectric point determination. Isoelectric points of the monoclonal antibodies were determined by chromatofocusing (9) . The 
Results
In vitro erythrocyte binding properties ofIgA-IC and IgGI-IC. Fig. 1 demonstrates that, compared to IgGl-IC, IgA-IC bind poorly to primate erythrocytes in vitro. This is most evident under conditions in which the erythrocytes or serum (complement source) are limited (Fig. 1) . Varying the incubation period from 10 to 60 min did not affect the relative binding of IgGl-IC vs. IgA-IC (data not shown). Fig. 2 for IgA-IC: 0.3±1.5%; both differences are not significantly different from zero by paired t test). Such differences in erythrocyte to IC binding may reflect differences in the density oferythrocyte CR1 receptors among baboons. Differences in density of erythrocyte CR1 receptors among humans have been noted previously and appear to be a genetically regulated characteristic (12) .
In vivo erythrocyte binding properties ofIgA-IC and IgGi-IC. Fig. 3 shows the sequential erythrocyte to IC binding data from the five in vivo experiments. As can be seen, the IgG 1-IC were efficiently bound by erythrocytes in all experiments. In contrast, IgA-IC were bound less well by erythrocytes. In some primates the percent of IgA-IC bound by erythrocytes in vivo was better than that observed in the in vitro experiments. This may reflect the fact that in vivo there was a great excess oferythrocyte CR I relative to IC, compared with the in vitro conditions used to assess IC to erythrocyte binding ( Figs. 1 and 2 ). Clearance ofIgA-IC and IgGi-ICfrom the circulation. Fig.  4 shows the clearance from the circulation of IgA-IC and IgG 1-IC. As can be seen, the IgA-IC were cleared from the circulation faster than IgG 1-IC in all experiments. This is shown by the fact that in each experiment IgA-IC and IgG I-IC were given at the same rate and in the same number of cpm, but in each experiment the peak IC level achieved was less for IgA-IC than for IgGl-IC (mean ratio IgA-IC/IgGl-IC at 120 s was 0.80±0.02, P < 0.001). The more rapid clearance ofIgA-IC was seen whether the IgA-IC was infused simultaneously with IgG I-IC (exps. 1-3) or sequentially (exps. 4 and 5). Clearance oflCfrom the circulation in relation to erythrocyte binding. To assess whether the speed with which the IC were cleared from the circulation was related to the degree to which IC were bound to erythrocytes, the IC clearance and the IC to erythrocyte binding events were analyzed during the period of rapid clearance, the 60-s period commencing immediately after cessation of the IC infusion. As discussed previously (1, 2) , this time period is chosen for analysis because the most rapid clearance of IC from the blood occurs during this time period. In addition, during this time period the blood IC level is affected only by the rate ofIC clearance, whereas before that time period, the blood IC level is affected by both the rate of IC infusion and the rate of IC clearance. At the start ofthe period of rapid clearance, 90±8% of the IgGl-IC and 70.4±7% of the IgA-IC injected were still present in the circulation.
To compare in the same primate, the rate of IC clearance to the level of IC to erythrocyte binding for each IC probe, the ratio percent IC bound to erythrocytes (IgA-IC/IgG I-IC), and the ratio, IC clearance rate (IgA-IC/IgG 1-IC), were calculated from the data ofthe period ofrapid clearance as follows: percent IC bound to erythrocytes for a given IC probe was taken as the mean of the percent IC bound at the 120-, 150-, and 180-s intervals; IC clearance rate for a given probe was taken as (cpm/ ml of blood at 120 s-cpm/ml of blood at 180 s)/cpm/ml of blood at 120 s. The data for all experiments is shown in Fig. 5 . As can be seen, the greater the disparity in IC to erythrocyte binding between IgA-IC and IgG1-IC, the faster was the clearance of IgA-IC relative to IgGl-IC (r = 0.958, P < 0.02).
Tissue uptake ofIgA-IC and IgG1-IC. The the isolated glomeruli. Indeed, the opposite is true, because, at the end of the experiment, the blood level of IgG 1-IC exceeded that of IgA-IC, IgA-IC deposited in glomeruli is actually greater than that shown. By comparing all of the estimated cpm in glomeruli to the total cpm in renal cortex, it can be calculated that in exps. 1-3, 1.8, 4.3, and 7.4%, respectively, of IC in kidney were deposited in glomeruli. Since glomeruli comprise -3-5% ofthe glomerular capillary network (13) , and since that approximate percentage of IC in kidney were deposited in glomeruli, it is evident that glomeruli trap IC roughly in proportion to their volume (or surface area). This finding is consistent with our previous studies, using IC composed of polyclonal antibodies, in both primates (unpublished observations) and nonprimates (5, 13) .
In exps. 4 and 5, fractional IC uptake by liver was estimated by measuring arterial-venous IC concentration differences. Consistent with our previous observations, there was nearly complete extraction of IC from the hepatic circulation for both IgA-IC and IgGl-IC. For exp. 4 there was >90% extraction of both IgA-IC and IgG 1-IC. For exp. 5 there was >97% extraction of both IgA-IC and IgG1-IC. Thus, the greater hepatic uptake of IgGl-IC cannot be ascribed to decreased capacity of the liver to trap IgA-IC. Rather, the decreased IgA-IC uptake by liver demonstrated in exps. 1-3 must be ascribed to decreased delivery rate of IgA-IC to liver. This is due to the lower blood level of IgA-IC which, in turn, is the result of a greater rate of IgA-IC deposition elsewhere in the vascular network.
In exps. 1-3, tissue levels of IC were also measured in all of the other major organs, as described in Methods. However, in all of these organs, the '251 and 131I cpm/gram of tissue were <100 cpm/g of tissue, and most were <50 cpm/g of tissue. Because of the low cpm/g of tissue in these organs, the 125I and '~'I cpm that is passively retained in the vascular space of these tissue contributed greatly to the total cpm/g of these tissues. This introduces a considerable error in estimating tissue uptake of IC, as discussed previously (5, 13) . Thus, under these experimental conditions, it was not possible to reliably estimate tissue IC uptake in organs other than kidney, lung, liver, and spleen. The range of the percent of the IgA-IC and of the IgG1-IC deposited in the major organs is as follows: liver IgA-IC, 31-58%; IgG1-IC, 40-67%; spleen IgA-IC, 6-18%; IgG1-IC, 7-21%; lungs IgA-IC, 15-15.8%; IgG1-IC, 7-1 1%; kidneys IgA-IC, 0.44-1.6%, IgG1-IC, 0.20-0.56%. These findings are similar to those we previously obtained using an IC probe composed of rabbit antibody/BSA (1) .
Biophysical properties ofthe IC Size ofIgA-IC vs. IgG1-IC. Large IC are cleared from the circulation more rapidly than small IC (2, 14) . To assess the possibility that differences in IC size could explain differences in IC clearance rates, portions of the IgA-IC and IgGI-IC preparations used in each experiment were centrifuged on isokinetic sucrose gradients. The size profile ofthe IC preparations, compiled from all experiments, is shown in Fig. 6 . These data indicate that the IgA-IC were actually smaller than the IgGl-IC. Thus, IgA-IC were cleared more rapidly from the circulation, despite their smaller size.
Antibody affinity. Antibody affinity, assessed by equilibrium dialysis, was similar for the IgA and IgGI antibodies (5.53 X 106 vs. 3.82 X 106 liters/mole, respectively).
Antibody charge. The pI of IgA vs. IgGI, assessed by chro0o matofocusing, showed that the IgA antibodies were more anionic (6, 23) . However, the IgA-IC were sufficiently large to achieve binding, if size alone were the determinant (see Fig. 6 (24) . The presumed greater electronegativity of IgA-IC might have been another factor diminishing binding of IgA-IC to erythrocytes, which normally have a negatively charged surface (25) . Finally, IC erythrocyte binding is a reversible process (26). Thus, the lower level of binding of IgA-IC might have been due to a greater susceptibility of these IC to be released from the-erythrocyte membrane by plasma factors.
The present study also seems relevant to the problem of ICmediated vasculitis in the following way. Hypocomplementemia is seen in virtually all patients with systemic vasculitis associated with deposition of IC (27) . Apparently, the hypocomplemen-3. The kidney is -0.4% of body weight, but receives -25% of cardiac output. The lung is -2.5% of body weight but receives 100% of cardiac output.
temia is the result of high rates of complement consumption caused by a large IC load which, in turn, is apparently responsible for the widespread vascular injury. The striking exception to this generalization is found in patients with vasculitis mediated largely by IgA-containing immune complexes (Henoch-Schonlein purpura) (27). These patients are not hypocomplementemic, despite the fact that the vasculitis is often widespread and the deposits contain large amounts of IgA-IC that have activated the alternative complement pathway (27) . The data of the present experiments suggest that in Henoch-Schonlein purpura, one possible reason for extensive IC deposition but no hypocomplementemia is that IgA-IC can induce relatively widespread tissue injury at relatively low rates of IC production, because IgA-IC are not efficiently bound to erythrocytes and, therefore, are not efficiently cleared from the circulation. Thus, with IgA-IC-mediated disease, it is possible that extensive vasculitis can be caused by relatively small IC loads, and for this reason, hypocomplementemia does not develop.
The present study provides evidence that the erythrocyte CR I system is a key component of a rapid and efficient mechanism for safely removing IC from the circulation. However, the erythrocyte CR1 system is also capable of functioning in other ways to defend against IC-mediated disease. Specifically, in vitro studies have shown that the erythrocyte CR1 can serve as a cofactor, which greatly increases Factor I-mediated degradation of C3b and C4b (28) . These actions inhibit the further activation of the complement cascade by causing degradation of the C3 convertase and the C5 convertase (28) . Other in vitro studies have shown that IC-bound C3b attached to erythrocyte CR1 are "processed" on the surface ofthe erythrocyte by Factor I, which results in release of the IC from the erythrocyte with the C3b moeity on the IC cleaved to C3d. This processing of C3b to C3d, which can then interact with CR2 receptors, may represent an immunologic signal (29) .
The way in which the clearing function and the processing function of the erythrocyte CR1 system relate in vivo is not clear. However, the greater speed of the erythrocyte clearing mechanism, relative to the erythrocyte CR1 processing mechanism, suggests that, in vivo, the first option is for the erythrocytebound IC to be delivered to liver and spleen for disposal. If that mechanism is impaired because, for example, the mononuclear phagocyte system of liver and spleen are unable to efficiently take up IC, then the processing function of the erythrocyte CR1 system may become dominant.
